SCHEMBL19869985

SCHEMBL19869985

Cn1cc(C(C)(C)C)c2cnccc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 15/20 0.46
BRD9 Q9H8M2 3/20 0.45
BRD7 Q9NPI1 3/20 0.45
TAF1 P21675 2/20 0.43
TGFBR1 P36897 2/20 0.43
ACVR1 Q04771 2/20 0.43
CREBBP Q92793 2/20 0.43
CECR2 Q9BXF3 2/20 0.43
BRPF1 P55201 1/20 0.43
BPTF Q12830 1/20 0.43
TAF1L Q8IZX4 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
ATAD2B Q9ULI0 1/20 0.43
NFATC1 O95644 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
CYP2D6 P10635 1/20 0.40
ACVR2B Q13705 1/20 0.40
BRD8 Q9H0E9 1/20 0.40
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19869619 0.94 BRD4 (0.44) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL23957951 0.83 BRD4 (0.35) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL24556448 0.81 BRD4 (0.46) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL24656777 0.80 DYRK1A (0.45) TGFBR1NFATC1GSK3BDYRK1ACYP2D6
SCHEMBL24654868 0.78 DYRK1A (0.56) TGFBR1NFATC1GSK3BDYRK1A
SCHEMBL8267803 0.78 BRD4 (0.55) BRD4BRD9BRD7
SCHEMBL19857646 0.77 HASPIN (0.49) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL21224912 0.77 BRD4 (0.45) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL16651749 0.77 BRD4 (0.45) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL23957955 0.76 KDM5A (0.34) BRD4BRD9BRD7TAF1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-09-21 US disclosed
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-02-09 US disclosed
EP-3265453-B1 NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 BOEHRINGER INGELHEIM INT (DE) 2022-06-29 EP disclosed
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-03 US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BRD9, BRD1, BRD2 BRD4 5/4885BRD9 1/4885BRD7 6/4885
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME HCCS, HAVCR2, HDGF BRD4 47/4885BRD9 141/4885BRD7 218/4885
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BRD9, BRD1, BRD2 BRD4 6/4885BRD9 1/4885BRD7 5/4885
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HMBS, AHCY BRD4 296/4885BRD9 433/4885BRD7 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.